Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.50 |
| ▸ | LDHA | P00338 | 2/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.43 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | TK2 | O00142 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419681 | 0.88 | KDM4E (0.46) | CCR2LDHAMCL1ALDH1A1CYP1A2 | |
| SCHEMBL416525 | 0.77 | SERPINE1 (0.38) | CCR2MCL1SERPINE1CNR2TK2 | |
| SCHEMBL7245116 | 0.73 | CCR2 (0.79) | CCR2LDHASERPINE1GPR35 | |
| SCHEMBL2933072 | 0.70 | MCL1 (0.67) | CCR2MCL1ALDH1A1CYP1A2POLB | |
| SCHEMBL13701158 | 0.69 | CCR2 (0.69) | CCR2MCL1ALDH1A1CYP1A2POLB | |
| SCHEMBL13308 | 0.68 | LDHA (1.00) | CCR2LDHAMCL1SERPINE1ALDH1A1 | |
| SCHEMBL27812794 | 0.67 | LDHA (0.69) | CCR2LDHAMCL1SERPINE1ALDH1A1 | |
| SCHEMBL7239402 | 0.67 | CCR2 (0.69) | CCR2LDHASERPINE1GPR35 | |
| SCHEMBL6300939 | 0.67 | CCR2 (1.00) | CCR2 | |
| SCHEMBL1422338 | 0.66 | MCL1 (0.62) | CCR2MCL1ALDH1A1CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO LTD (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785473-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2607348-A2 | Plasminogen Activator Inhibitor-1 Inhibitor | Renascience CO., LTD. (JP) | 2013-06-26 | — | — | EP | disclosed |
| EP-2415755-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Renascience CO., LTD. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | CCR2 3079/4885LDHA 2698/4885MCL1 1685/4885 |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | CCR2 3079/4885LDHA 2698/4885MCL1 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.